Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 7/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | F3 | P13726 | 1/20 | 0.45 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20575294 | 1.00 | NAMPT (0.47) | NAMPTHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL2838687 | 0.92 | NAMPT (0.57) | NAMPTHDAC1 | |
| SCHEMBL2839446 | 0.92 | HDAC1 (0.45) | NAMPTHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL2841247 | 0.91 | NAMPT (0.44) | NAMPTHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL2834642 | 0.89 | NAMPT (0.48) | NAMPTADRB2ADRB1ADRB3LMNA | |
| SCHEMBL2836973 | 0.87 | ITGB3 (0.48) | NAMPTHDAC1ADRB2ADRB1ADRB3 | |
| SCHEMBL2839356 | 0.85 | NAMPT (0.47) | NAMPTADRB2ADRB1ADRB3LMNA | |
| SCHEMBL2836468 | 0.85 | ITGB3 (0.49) | NAMPTHDAC1ADRB2ADRB1ADRB3 | |
| SCHEMBL20575296 | 0.84 | NAMPT (0.47) | NAMPTHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL2839023 | 0.83 | TSHR (0.50) | NAMPTHDAC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1282602-B1 | PROPANOIC ACID DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA ITALIA SPA (IT) | 2005-09-21 | — | — | EP | claimed |
| US-20030144311-A1 | Propanoic acid derivatives as intergrin receptor antagonists | PHARMACIA ITALIA S.P.A. (IT) | 2003-07-31 | — | — | US | claimed |
| US-20180344803-A1 | Methods and Compositions For the Treatment of Proteinuric Diseases | THE GENERAL HOSPITAL CORPORATION | 2018-12-06 | — | — | US | disclosed |
| US-20160296592-A1 | Methods and Compositions for the Treatment of Proteinuric Diseases | THE GENERAL HOSPITAL CORPORATION | 2016-10-13 | — | — | US | disclosed |
| US-9345739-B2 | Methods and compositions for the treatment of proteinuric diseases | THE GENERAL HOSPITAL CORPORATION (US) | 2016-05-24 | — | — | US | disclosed |
| EP-2730282-A1 | Methods and compositions for the treatment of proteinuric diseases | The General Hospital Corporation (US) | 2014-05-14 | — | — | EP | disclosed |
| US-20100297139-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | THE GENERAL HOSPITAL CORPORATION | 2010-11-25 | — | — | US | disclosed |
| WO-2009061448-A9 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | THE GENERAL HOSPITAL CORPORATION (US) | 2009-08-13 | — | — | WO | disclosed |
| US-6974828-B2 | Propanoic acid derivatives as intergrin receptor antagonists | PHARMACIA ITALIA S.P.A. (IT) | 2005-12-13 | — | — | US | disclosed |
| EP-1282602-B1 | PROPANOIC ACID DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA ITALIA SPA (IT) | 2005-09-21 | — | — | EP | disclosed |
| US-20030144311-A1 | Propanoic acid derivatives as intergrin receptor antagonists | PHARMACIA ITALIA S.P.A. (IT) | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160296592-A1 | Methods and Compositions for the Treatment of Proteinuric Diseases | ITGB3, PLAUR, PROC | NAMPT 357/4885HDAC1 2174/4885HDAC3 647/4885 |
| US-20180344803-A1 | Methods and Compositions For the Treatment of Proteinuric Diseases | ITGB3, PLAUR, PROC | NAMPT 357/4885HDAC1 2174/4885HDAC3 647/4885 |
| US-20100297139-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | ITGB3, PLAUR, PROC | NAMPT 357/4885HDAC1 2174/4885HDAC3 647/4885 |
| US-20030144311-A1 | Propanoic acid derivatives as intergrin receptor antagonists | ITGB3, HCAR3, ADRB3 | NAMPT 3667/4885HDAC1 3299/4885HDAC3 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.